Eli Lilly is a global pharmaceutical company dedicated to discovering, developing, manufacturing, and marketing innovative medicines that address some of the world's most challenging health issues. The company focuses on areas such as diabetes, oncology, immunology, and neurodegenerative diseases, providing a wide range of treatments designed to improve patient outcomes and quality of life. Eli Lilly is committed to scientific advancement and works collaboratively with healthcare professionals and researchers to bring new therapies and solutions to market, ensuring access to life-saving medications for patients around the globe. Read More
Saynor told Reuters that the proposal, put forth by Novartis and Sanofi in a letter to the Financial Times on Wednesday, overlooks the structural drivers of high drug prices in the United States and will not address global pricing inequities.
HSBC noted that while the market has assumed a significant market share for Eli Lilly, these expectations may be revised in light of potential economic sensitivity to the adoption curve for weight loss drugs.
A highly volatile stock can deliver big gains - or just as easily wipe out a portfolio if things go south.
While some investors embrace risk, mistakes can be costly for those who aren’t prepared.
Enrico Canal Bruland, vice president and general manager of Novo's Thai subsidiary, told Reuters that the firm received approval from the Thai FDA in 2023.
Pfizer highlighted positive late-stage results for its experimental bladder cancer drug, sasanlimab, as it looks to strengthen its oncology portfolio and offset losses from recent setbacks in its weight-loss drug program.
Jim Cramer is preparing investors for another action-packed week on Wall Street, packed with earnings reports from major tech players and key economic updates.
Viking Therapeutics stock is trying to push higher as investors attempt to sort out a report that delivered no real news that investors hadn’t already heard.
Groundbreaking ALS Therapy Shows Remarkable Survival Benefits as NeuroSense Continues to Advance Toward Potential Partnership with Pharma Giant (NASDAQ: NRSN)*
While profitability is essential, it doesn’t guarantee long-term success.
Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my opportunity".
The company unveiled three seventh-generation robotaxi models developed through its partnerships with Toyota, BAIC, and GAC at the Shanghai International Automobile Industry Exhibition on Wednesday.
According to a CNBC report, the company filed lawsuits against Mochi Health, Fella Health, Willow Health, and Henry Med on Wednesday, alleging that they deceived consumers about “untested, unapproved drugs.”
Take a deep dive into Eli Lilly's latest clinical GLP-1 results that sent shares soaring. The company has a big opportunity to serve needle-phobic patients.
